InMed Pharmaceuticals Inc. (INM) stock
INMNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as MTRI
$1.37+0.05 (+3.44%)
Close on Oct 19, 2026Market cap $83.97MP/E –Yield –
InMed Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
InMed Pharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $4.51M, down 6.7% year over year. For fiscal 2025 it was $4.94M, up 7.5% from the year before. The highest annual figure on record is $4.94M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.94M | +7.5% |
| FY2024 | Jun 30, 2024 | $4.60M | +11.2% |
| FY2023 | Jun 30, 2023 | $4.14M | +279.6% |
| FY2022 | Jun 30, 2022 | $1.09M | -42.8% |
| FY2021 | Jun 30, 2021 | $1.90M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $820.19K | -26.2% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $1.12M | -11.4% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $1.30M | +1.7% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $1.26M | +7.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $1.11M | -10.4% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $1.26M | +40.2% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $1.28M | -44.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $1.17M | +13.4% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $1.24M | +164.0% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $901.86K | +181.1% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $2.31M | +349.0% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $1.03M | +234.0% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $469.78K | +77.2% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $320.79K | -63.6% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $514.76K | +17.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $309.59K | +11.8% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $265.09K | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $880.63K | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $437.31K | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $276.79K | – |
See a number that looks wrong?